AICXD Applied Imaging (MM)

Applied Imaging Announces Collaboration With the University of Vermont College of Medicine SAN JOSE, Calif., May 26 /PRNewswire-FirstCall/ -- Applied Imaging Corp. (NASDAQ:AICXD) and the University of Vermont (UVM) College of Medicine, today announced a collaboration between Applied Imaging's wholly-owned subsidiary, CTC, Inc. (CTC) and UVM to further develop and clinically validate proprietary technology to detect, quantify and characterize circulating tumor cells in the blood of cancer patients. David Krag, M.D., S.D. Ireland Professor of Surgical Oncology, will lead the program at UVM. Tumor cells are known to be shed from cancerous tumors (including breast, ovarian, colorectal, prostate and lung cancers) into the blood. These cells contain critical information about the status and progression of the disease. With an initial focus on breast cancer, CTC is developing a system for detecting and evaluating these tumor cells in a routine blood sample. CTC's approach incorporates a unique cell selection technology coupled with Applied Imaging's proprietary Ariol(R) automated cell imaging system. "Dr. Krag is a well-recognized leader in the application of new technologies that address important health care initiatives and we believe that this collaboration will help enormously in our goal of developing clinically-validated technology for improving the lives of breast cancer patients," commented Diane Day, Corporate Vice President of Applied Imaging and General Manager of CTC Inc. "We have already installed an Ariol(R) system in Dr. Krag's laboratory." "I am very excited about the prospects for this partnership, because our translational research programs have been largely focused on making improvements to breast cancer care, including the development and application of radio-guided surgical resection of sentinel nodes," said Dr. Krag. "It is the undetected cancer cells that remain in a patient following definitive surgery, radiation, and systemic therapy that often grow and lead to the demise of the patient. The more we understand about these remaining cells, the closer we are to curing breast cancer. We believe that this research holds great promise for improving breast cancer management, and look forward to working closely with CTC to perfect technology that helps to satisfy the critical needs in this area." Timely assessment of patient status through the analysis of circulating tumor cells has the potential to aid the oncologist in improving patient care. It could also provide the potential for earlier detection of disease. According to the American Cancer Society (ACS), breast cancer is the leading cause of death for American women between the ages of 35 and 54. ACS forecasts that there will be over 192,000 new, invasive breast cancer cases in the U.S. this year alone. Invasive breast cancer causes about 40,000 deaths per year. Code: AICXG About Applied Imaging Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology laboratories. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 3,500 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients. More information about Applied Imaging can be found at http://www.aicorp.com/. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the ability of CTC, Inc. to develop proprietary technology that detects circulating tumor cells for, among other applications, the management of breast cancer patients; and the success of the collaboration with University of Vermont. Forward looking statements address matters that are subject to a number of risks, uncertainties and other factors, which are detailed in the Company's periodic filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors include, but are not limited to, CTC's ability to research, develop, patent and commercialize new technology to detect and characterize circulating tumor cells in blood. The forward-looking statements in this news release are made as of May 26, 2005, and Applied Imaging is under no obligation to revise or update these statements. CCG Investor Relations Crocker Coulson, President 10960 Wilshire Blvd., Suite 2050 Los Angeles, CA 90024 310-231-8600, Ext. 103 Applied Imaging Corp. Diane Day, General Manager, CTC, Inc. 120 Baytech Drive San Jose, CA 95134 (408) 719-6400 DATASOURCE: Applied Imaging Corp. CONTACT: Crocker Coulson, President of CCG Investor Relations, +1-310-231-8600, ext. 103, ; or Diane Day, General Manager of CTC, Inc., +1-408-719-6400, ; both for Applied Imaging Corp. Web site: http://www.aicorp.com/

Copyright